Evidence map›Paper›PMID 31176512›Full record

ArticleTrends in microbiology2019

Resistance Reversed in KatG Mutants of Mycobacterium tuberculosis.

Pablo Machado, Cristiano Valim Bizarro, Luiz Augusto Basso

Open access · hybridAbstract readComment
PubMed Publisher
In one paragraph

Article in Trends in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Frontiers in cellular and infection microbiology · 2021
    Article
  3. Molecules (Basel, Switzerland) · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Pablo MachadoInstituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Centro de Pesquisas em Biologia (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil; Escola de Ciências da Saúde, PUCRS, Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: pablo.machado@pucrs.br.
Cristiano Valim BizarroInstituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Centro de Pesquisas em Biologia (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil; Escola de Ciências, PUCRS, Rio Grande do Sul, Brazil.
Luiz Augusto BassoInstituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Centro de Pesquisas em Biologia (CPBMF), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil; Escola de Ciências, PUCRS, Rio Grande do Sul, Brazil. Electronic address: luiz.basso@pucrs.br.
Pontifícia Universidade Católica do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A peptidomimetic containing a thiazolo ring-fused 2-pyridone (C10) has now been reported to inhibit hypoxia-induced tolerance to isoniazid (INH) in Mycobacterium tuberculosis (Flentie et al., Proc. Natl. Acad. Sci. U. S. A., 2019). The C10 compound could also potentiate the bactericidal activity in aerobically grown bacilli, prevented selection of drug-resistant strains, and reversed INH resistance in katG (catalase-peroxidase) mutants.

Indexed as

IsoniazidMycobacterium tuberculosisBacterial ProteinsCatalaseDrug Resistance, BacterialBacterial ProteinsCatalaseIsoniazidcatalase-peroxidasedrug resistanceisoniazidkatGrespirationtuberculosis

Identifiers

PMID31176512
OpenAlexW2948978997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.